kinesin family member 6Genealiases: C6orf102 · dJ1043E3.1 · dJ137F1.4 · dJ188D3.1
Q-omics provides the consensus-scored KIF6 profile across patient tissues and cancer cell-line models. KIF6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KIF6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KIF6 RNA expression shows 17,199 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where KIF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF6 survival associations across molecular data types. KIF6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF6 RNA expression–survival associations across cancer types. High KIF6 expression shows unfavorable associations in HNSC, but favorable associations in UVM, ACC, MESO, PAAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KIF6 RNA expression.
This table summarizes KIF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF6 shows lower tumor expression in KIRC, KICH, THCA, LUAD, LUSC and COAD. The KIRC box plot shows higher KIF6 RNA expression in normal versus tumor tissue (log2 FC = −0.616, t-test p < 0.001).
This table shows molecular features associated with KIF6 in patient tissues and cancer cell lines. In patient samples, KIF6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
